Hwa Guang Announces Shareholder Approval to Lift Non-Compete Restriction on Director Fan Pu

Release Date: June 27, 2026 Statement Date: June 26, 2026 Statement Time: 17:37:35 Company Code: 4737 Company Name: Hwa Guang Subject: Announcement of the Resolution Passed at the 2026 Annual General Meeting to Lift the Non-Compete Restriction on a Director Applicable Clause: Item 21 Factual Date: June 26, 2026

Details: 1. Shareholder Meeting Resolution Date: 06/26/2026

2. Name and Title of Director Permitted to Engage in Competitive Activities: Director: Fan Pu, Representative of Tonghua Dongbao Pharmaceutical Co., Ltd.

3. Permitted Competitive Activities: Lifting the restriction under Article 209 of the Company Act on Fan Pu, Director, regarding his engagement in biotechnology, bio-technology, biopharmaceuticals, and biotech industry advisory roles at other companies, provided that such activities do not harm the interests of the Company.

4. Duration of Permitted Competitive Activities: During the term of his directorship at the Company.

5. Voting Results (as required by Article 209 of the Company Act): Total voting rights present at the meeting: 53,304,833 Votes in favor: 52,249,757 (98.02%) Votes against: 59,213 (0.11%) Invalid votes: 0 (0%) Abstentions / Non-votes: 995,863 (1.86%) Result: The resolution was approved as proposed following shareholder voting.

6. Name and Title of Director Engaging in Competitive Activities with Mainland China-Based Enterprises (Enter "Not Applicable" if not applicable): Fan Pu, Representative of Tonghua Dongbao Pharmaceutical Co., Ltd.

7. Name and Position Held at the Mainland China-Based Enterprise: Director - Tonghua Dongbao Pharmaceutical Co., Ltd., appointing legal representative Mr. Fan Pu as Vice President; General Manager and Executive Director of Tianjin Runxin Enterprise Management Co., Ltd.; Representative of the Managing Partner of Tianjin Runhe Enterprise Management Partnership; Chairman of Benyuan Zhengyang Gene Technology Co., Ltd.; Director of Dongbao International (Hong Kong) Limited.

8. Address of the Mainland China-Based Enterprise: (1) Tonghua Dongbao Pharmaceutical Co., Ltd.: Dongbao Xincun, Tonghua County, Jilin Province (2) Tianjin Runxin Enterprise Management Co., Ltd.: Room 201, Building K10, International Enterprise Community, Changyuan Road, Wuqing Development Zone, Tianjin (3) Tianjin Runhe Enterprise Management Partnership: Room 201, Building K10, International Enterprise Community, Changyuan Road, Wuqing Development Zone, Tianjin (4) Benyuan Zhengyang Gene Technology Co., Ltd.: No. 6 Yongchang Zhong Road, Beijing Economic-Technological Development Area, Beijing (5) Dongbao International (Hong Kong) Limited: UNIT 1021 BEVERLEY COMMERCIAL CENTRE 87-105 CHATHAM ROAD SOUTH TSIM SHA TSUI HK

9. Business Scope of the Mainland China-Based Enterprise: (1) Tonghua Dongbao Pharmaceutical Co., Ltd.: Hard capsules, tablets (including hormone-containing), granules, small-volume injections, active pharmaceutical ingredients (recombinant human insulin), biotechnology products (recombinant human insulin injections), surgical, emergency, and diagnostic equipment and instruments, injection and puncture devices, clinical testing analyzers and diagnostic reagents (including diagnostic reagents), medical laboratory and basic equipment. Primarily engaged in R&D, manufacturing, and sales of biopharmaceuticals, traditional Chinese medicine, and chemical drugs in the fields of diabetes and endocrinology. (2) Tianjin Runxin Enterprise Management Co., Ltd.: Enterprise management, management consulting. (3) Tianjin Runhe Enterprise Management Partnership: Enterprise management, marketing planning, and information consulting. (4) Benyuan Zhengyang Gene Technology Co., Ltd.: Research and development of new gene diagnosis and therapy technologies, production and sales of related products permitted by policy, research and development in the field of biotechnology, and industrial investment. (5) Dongbao International (Hong Kong) Limited: Pharmaceutical import and export, import/export agency, supply chain management services, economic information consulting services.

10. Impact on the Company's Financial and Business Operations: None

11. If the Director has invested in the said Mainland China-based enterprise, the investment amount and ownership ratio: Director Fan Pu, representative of Tonghua Dongbao Pharmaceutical Co., Ltd., investments in Mainland China entities: (1) Tianjin Runxin Enterprise Management Co., Ltd.: Investment amount RMB 5,000, ownership ratio 16.6667% (2) Tianjin Runhe Enterprise Management Partnership: Investment amount RMB 1,705,100, ownership ratio 4.7736%

12. Other Matters to be Disclosed: None